Cargando…
Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy
Designing an RNA-interacting molecule that displays high therapeutic efficacy while retaining specificity within a broad concentration range remains a challenging task. Risdiplam is an FDA-approved small molecule for the treatment of spinal muscular atrophy (SMA), the leading genetic cause of infant...
Autores principales: | Ottesen, Eric W, Singh, Natalia N, Luo, Diou, Kaas, Bailey, Gillette, Benjamin J, Seo, Joonbae, Jorgensen, Hannah J, Singh, Ravindra N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325915/ https://www.ncbi.nlm.nih.gov/pubmed/37026480 http://dx.doi.org/10.1093/nar/gkad259 |
Ejemplares similares
-
Activation of a cryptic 5′ splice site reverses the impact of pathogenic splice site mutations in the spinal muscular atrophy gene
por: Singh, Natalia N., et al.
Publicado: (2017) -
Human Survival Motor Neuron genes generate a vast repertoire of circular RNAs
por: Ottesen, Eric W, et al.
Publicado: (2019) -
An intronic structure enabled by a long-distance interaction serves as a novel target for splicing correction in spinal muscular atrophy
por: Singh, Natalia N., et al.
Publicado: (2013) -
Functional characterization of alternatively spliced human SECISBP2 transcript variants
por: Papp, Laura V., et al.
Publicado: (2008) -
Sam68 binds Alu-rich introns in SMN and promotes pre-mRNA circularization
por: Pagliarini, Vittoria, et al.
Publicado: (2020)